Karyopharm Therapeutics | KPTI - Gross Profit On Sales


Karyopharm Therapeutics reported $33.72M in Gross Profit on Sales for its fiscal quarter ending in March of 2026.





Gross Profit On Sales Change Date
AbbVie USD 14.39B 1.85B Jun/2026
Abbott USD 6.65B 787M Jun/2026
Amgen USD 5.87B 1.02B Mar/2026
AstraZeneca USD 12.86B 251M Jun/2026
BioCryst Pharmaceuticals USD 214.41M 61.36M Jun/2026
Bristol-Myers Squibb USD 9.26B 1.19B Jun/2026
Eli Lilly USD 16.22B 301.7M Mar/2026
Enanta Pharmaceuticals -22.29M 23.75M Dec/2024
GlaxoSmithKline GBP 6.51B 757M Jun/2026
Incyte USD 1.57B 400.89M Jun/2026
J&J USD 18.55B 6M Sep/2026
Karyopharm Therapeutics USD 33.72M 1.13M Mar/2026
MacroGenics USD 11.24M 19.87M Mar/2026
Merck USD 12.09B 1.24B Mar/2026
Nektar Therapeutics USD 10.86M 10.95M Mar/2026
Novartis USD 11.24B 1.18B Jun/2026
Novartis USD 10.07B 758M Mar/2026
Pfizer USD -248M 11.29B Jun/2026
Regeneron Pharmaceuticals USD 3.71B 778.2M Jun/2026
Roche Holding CHF 22.69B 600M Jun/2026
Sangamo BioSciences -2.39M 1.09M Jun/2024
Takeda JPY 813.22B 124.39B Jun/2026
Tectonic Therapeutic USD 0 0 Mar/2025
TG Therapeutics USD 199.14M 27.73M Jun/2026
Ultragenyx Pharmaceutical USD 180M 74M Jun/2026
Xencor USD 51.22M 46.7M Jun/2026